BioMarin's Vimizim Gets NICE Final Nod
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceuticals' enzyme replacement therapy, Vimizim (elosulfase alfa), has been given the thumbs up by NICE, the UK's health technology appraisal body, for use on the National Health System to treat mucopolysaccharidosis patients.